In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Palatin Technologies, Inc.. Trade Record

AMEX:PTN Palatin Technologies, Inc. stock gains 16.42% Exit Jun 24, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart PTN Jun 21, 2019, priceSeries
About Palatin Technologies, Inc.

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include Melanocortin receptor-4 (MC4r) peptides and small molecule agonists that are under the preclinical trials for the treatment of conditions responsive to MC4r activation, including female sexual dysfunction, HSDD, erectile dysfunction, obesity, and diabetes; and Melanocortin receptor-1 peptide agonists, which are under preclinical studies for the treatment of inflammatory and dermatologic disease indications, as well as other Melanocortin receptors. In addition, the company is involved in the development of natriuretic peptide receptor-specific programs, including PL-3994, a natriuretic peptide receptor-A, which is in Phase II clinical studies for treatment of heart failure, acute exacerbations of asthma, and refractory hypertension. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Trade Information
Trade Type
LONG
ReliabilityScore™
87.74
Entry Date
Jun 21, 2019
Entry Price
1.34
Sell Date
Jun 24, 2019
Sell Price
1.56
Net Gain
16.42%
Hold Time
1 Trading Days